SCHEDULE: Wellington Management Discloses 7.2% Stake in CG Oncology

Wellington Management Group LLP and its affiliates have reported a 7.2% beneficial ownership stake in CG Oncology, Inc. as of September 30, 2025.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, collectively reported beneficial ownership of CG Oncology, Inc. common stock.
• The aggregate amount beneficially owned by the group is 5,512,779 shares.
• This represents 7.2% of the class of CG Oncology, Inc. common stock.
• The reporting persons hold shared voting power over 4,898,682 shares and shared dispositive power over 5,512,779 shares.
• The stake was acquired and is held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The securities are owned of record by clients of Wellington's investment advisers, with no single client known to own more than 5% of the class.

Sentiment

Score: 6

Explanation: The filing is a neutral, factual disclosure of beneficial ownership. However, the acquisition of a significant stake by a large, reputable investment firm like Wellington Management can be perceived as a positive signal by the market, indicating institutional confidence in the issuer, hence a slightly positive score.

Positives

• A significant stake by a major investment firm like Wellington Management can signal institutional confidence in CG Oncology's long-term prospects.
• The passive nature of the filing (Schedule 13G) indicates the investment is for ordinary course of business, not an activist play, which can be viewed positively by management.

Future Outlook

This filing does not contain forward-looking statements or guidance from CG Oncology, Inc. It solely reports beneficial ownership by Wellington Management Group LLP and its affiliates.

Industry Context

The disclosure of a significant stake by a prominent asset manager like Wellington Management in a biotechnology company like CG Oncology could be interpreted by the market as a vote of confidence in the oncology sector or CG Oncology's specific pipeline and market position.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially lead to positive share price movement.
• Management: A large, passive institutional investor can provide stability to the shareholder base.

Key Dates

Keywords

CG Oncology, Wellington Management, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Schedule 13G, Biotechnology, Oncology